Our mission is to abolish kidney cancer as a threat to the life and health of patients by supporting patient advocacy and research by supporting government and industry research funding, facilitating research collaborations, and offering direct financial support for clinical and laboratory researchers with promising ideas. Together, we can find the cure.
Join Us for D.C. Advocacy Days
On March 9-10, members of the kidney cancer community once again gather in Washington, D.C.
Join us as we educate policymakers and our elected representatives on issues affecting the kidney cancer community. Your voice is essential to securing funding for the NIH/NCI and protect funding for the KCRP. As recently as 2016, zero dollars were allocated for kidney cancer research. In 2020, that number is $40 million, and we have the support of our community to thank for that.
On Monday, March 9th, we will have a classroom session at the Hamilton Hotel. On Tuesday, we head to Capitol Hill.
Lift your voice with ours! Let us know that you plan to join us for D.C. Advocacy Days in March.
Funded Research
Proceeds from our Rock the Cure events have been used to explore exciting approaches to generate individualized vaccines for kidney cancer patients. The approach will use fresh biopsies from kidney cancer patients to accurately represent their current cancer immune profile. The cells are then cultured and multiplied using a novel cell culture technique and can serve in the future as the basis for a patient specific whole cell or RNA vaccine. The advantage of this approach is that it not only directs the immune system to the specific mutations of the tumor, but also other over expressed common and rare normal proteins and activated retroviruses. Thus, the full repertoire of targets for the immune system will be displayed. While vaccines in the past have been met with moderate benefit at best, they are now poised to synergize with the modern immunotherapy revolution of immune checkpoint inhibitors.
My death sentence was commuted by something called RADVAX — a clinical trial in its second phase being run by Dr. Hans Hammers, a recent Johns Hopkins transplant to UT Southwestern. The trial is being funded by KidneyCAN.
KCRS19
The first annual Kidney Cancer Research Summit took place on September 12-13, 2019. Led by Dr. Toni Choueiri (Dana Farber Cancer Institute) and Dr. Hans Hammers (University of Texas Southwest Medical Center), this event brought together some of the most promising ideas for treatment.
KCRS Montage Video from KidneyCAN on Vimeo.
From Our Blog
This Week: RADVAX at ASCO GU
We are so proud to see Dr. Hans Hammers's clinical trial of RADVAX selected for presentation at ASCO GU 2020.
What Kidney Cancer Research Looks Like: SUNY Upstate Medical University
In January, the KidneyCAN team traveled to Syracuse, New York to visit the SUNY (State University of New York)
A New Era for the FDA: Our Perspective
In the past, the work of the Food and Drug Administration was often bogged down by bureaucratic processes and the
Since our inception in 2016, we have proudly given over $725,000 to Kidney Cancer Research!
WE ARE A GRASSROOTS ORGANIZATION DEDICATED TO MAKING A DIFFERENCE IN THE KIDNEY CANCER COMMUNITY
Funded major projects to date include:
-
RADVAX investigator led immunotherapy trial for 25 advanced kidney cancer patients at UT Southwestern combining Nivolumab, Ipilimumab and SBRT.
-
Support of UT Southwestern’s Kidney Cancer Research Program. 1 of only 2 SPOREs (Specialized Programs of Research Excellence) for Kidney Cancer in the US.
Our primary sources of support are donations from the general public and fundraising.
Please enter your information below: